Outcome states of colorectal cancer: Identification and description using patient focus groups

American Journal of Gastroenterology

Volumn 93, Issue 9, 1998, Pages 1491-1497

  Ness, Reid M ^a   Holmes, Ann ^b   Klein, Robert ^b   Greene, James ^b   Dittus, Robert ^b  

^a WISHARD MEMORIAL HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CLINICAL ARTICLE; COGNITION; COLORECTAL CANCER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FATIGUE; FEAR; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SEXUAL FUNCTION; SOCIAL INTERACTION; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FEMALE; FOCUS GROUPS; HUMANS; MALE; MIDDLE AGED; MORBIDITY; OSTOMY; QUALITY-ADJUSTED LIFE YEARS; RECTAL NEOPLASMS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 0032173264     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00350-5     Document Type: Article

References (39)

1. 1. Parker SL, Tong T, Belen S, et al. Cancer Statistics, 1997. CA Cancer J Clin 1997;47:5-27.
2. 2. Winawer SJ, Zauber AG, Ho MN, et al. Prevention of colorectal cancer by colonoscopic polypectomy. N Engl J Med 1993;329:1977-87.
3. 3. Winawer SJ, Zauber AG, O'Brien MJ, et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. N Engl J Med 1993;328:901-6.
4. 4. Mandel JS, Bond JH, Church TR, et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota colon cancer study. N Engl J Med 1993;328:1365-71.
5. 5. Kronborg O, Fenger C, Worm J, et al. Causes of death during the first 5 years of a randomized trial of mass screening for colorectal cancer with fecal occult blood test. Scand J Gastroenterol 1992;27:47-52.
6. 6. Winawer SJ, Flehinger BJ, Schottenfeld D, et al. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993;85:1311-8.
7. 7. Hardcastle JD, Armitage NC, Chamberlain J, et al. Fecal occult blood screening for colorectal cancer in the general population. Results of a controlled trial. Cancer 1986;58:397-403.
8. 8. Kewenter J, Brevinge H, Engaras B, et al. Results of screening, rescreening, and follow-up in a prospective randomized study for detection of colorectal cancer by fecal occult blood testing. Results for 68,308 subjects. Scand J Gastroenterol 1994;29:468-73.
9. 9. Russell LB, Gold MR, Siegel JE, et al. The role of cost-effectiveness analysis in health and medicine. JAMA 1996;276:1172-7.
10. 10. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996;276: 1253-8.
11. 11. Kaplan RM, Feeny D, Revicki DA. Methods for assessing relative importance in preference based outcome measures. Quality Life Res 1993;2:467-73.
12. 12. Boyd NF, Sutherland HJ, Heasman KZ. Whose utilities for decision analysis? Med Decis Making 1990;10:58-67.
13. 13. Sprangers MAG, Taal BG, Aaronson NK, et al. Quality of life in colorectal cancer: Stoma vs. nonstoma patients. Dis Colon Rectum 1995;38:361-9.
14. 14. Stewart DW, Shandasani PN. Focus groups theory and practice. Newbury Park, CA: Sage Publications, 1990.
15. 15. Cohen AM, Minsky BD, Schilsky RL. Cancer of the colon. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997:1144-97.
16. 16. Cohen AM, Minsky BD, Schilsky RL. Cancer of the rectum. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: Principles and practice of oncology. Philadelphia: Lippincott-Raven, 1997: 1197-1234.
17. 17. Moertel CG, Fleming TR, MacDonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990;322:352-8.
18. 18. IMPACT Investigators. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 1995;345:939-44.
19. 19. Enker WE. Potency, cure, and local control in the operative treatment of rectal cancer. Arch Surg 1992;127:1396-1402.
20. 20. van Driel MF, Weymar Schultz WCM, van de Weil HBM, et al. Female functioning after radical surgical treatment of rectal and bladder cancer. Euro J Surg Oncol 1993;19:183-7.
21. 21. Krook JE, Moertel CG, Gunderson LL, et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991;324: 709-15.
22. 22. O'Connell MJ, Martenson JA, Wieand HS, et al. Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 1994;331: 502-7.
23. 23. Glimelius B, Hoffman K, Graf W, et al. Quality of life during chemotherapy in patients with symptomatic advanced colorectal cancer. Cancer 1994;73:556-62.
24. 24. Weeks J. Assessing utilities for health states. Proc Am Soc Clin Oncol 1997;16:353-5.
25. 25. Smith R, Dobson M. Measuring utility values for QALY's: Two methodologicissues. Health Economics 1993;2:349-55.
26. 26. Hall J, Gerard K, Salkeld G, et al. A cost-utility analysis of mammography screening in Australia. Soc Sc Med 1993;34:993-1004.
27. 27. Danigelis NL, Roberson NL, Worden JK, et al. Breast screening by African-American women: Insights from a household survey and focus groups. Am J Prev Med 1995;11:311-7.
28. 28. Clark DO. Age, socioeconomic status, and exercise self-efficacy. Gerontol 1996;36:157-64.
29. 29. Robinson SB, Ashley M, Haynes MA. Attitude of African-Americans regarding prostate cancer clinical trials. J Comm Health 1996;21:77-87.
30. 30. Cooper-Patrick L, Powe NR, Jenckes MW, et al. Identification of patient attitudes and preferences regarding treatment of depression. J Gen Intern Med 1997;12:431-8.
31. 31. Jennings KM. Getting a Pap smear: Focus group responses of African American and Latina women. Onc Nurs Forum 1997;24:827-35.
32. 32. Froberg DG, Kane RL. Methodology for measuring health state preferences - I: Measurement strategies. J Clin Epidemiol 1989;42:345-54.
33. 33. Eberst RM. Defining health: A multidimensional model. JOSH 1984; 54:99-104.
34. 34. Rowland JH. Outcomes assessment: Cancer-specific quality-of-life measures - beyond the research setting. Proc Am Soc Clin Oncol 1997;16:342-9.
35. 35. Fletcher A. Quality-of-life measurements in the evaluation of treatment: proposed guidelines. Br J Clin Pharmac 1995;39:217-22.
36. 36. Fitzpatrick R, Fletcher A, Gore S, et al. Quality of life measures in health care. I: Applications and issues in assessment. Br Med J 1992; 305:1074-7.
37. 37. Patrick DL, Erickson P. Health status and health policy. New York: Oxford University Press, 1993.
38. 38. Miller GA. The magical number seven plus or minus two: Some limits on our capacity to process information. Psychol Rev 1956;63:81-97.
39. 39. Froberg DG, Kane RL. Methodology for measuring health state preferences - II: Scaling methods. J Clin Epidemiol 1989;42:459-71.